Navigation Links
Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium
Date:12/8/2009

ients with early metastasis risk - patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting-edge genomics platform for tumor gene expression profiling, the company's tests help physicians more accurately tailor cancer treatments. Agendia markets three products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

SOURCE Agendia B.V.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Agendia Expands Laboratory Capacity at New Amsterdam Headquarters to Meet Increasing Demand for Services Worldwide
2. Agendia Appoints Oncologist Richard A. Bender as Vice President and Chief Medical Officer
3. Agendias MammaPrint(R), the Only FDA-Cleared Breast Cancer Prognosis Test, is Now Widely Available to U.S. Patients
4. Time Magazine Names Agendia Test a Best Invention of 2007
5. Frost & Sullivan: E-Healthcare in Western Europe Presents a Significant Market Opportunity for Wireless Technologies
6. Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765
7. City of Hope Researchers Present Data on more than 30 Studies During American Society of Hematology Meeting Dec. 5 to 8 in New Orleans
8. Hospice Foundation of America Presents Webinar on Bereavement Camps for Kids: Benefits and Challenges
9. NBTY To Webcast Presentation; Wedbush Securities California Dreamin Mac Conference; Announces Preliminary Unaudited Net Sales Results For November 2009
10. Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference
11. Makers of Powerful Painkillers Present Safety Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2014)... policymakers consider ways to ease prohibitions on marijuana, the ... over the past century may provide valuable lessons, according ... that legalized marijuana in Colorado and Washington for recreational ... how to best allow the production, sales and the ... related social ills. , A new study published online ...
(Date:4/20/2014)... Researchers may have identified key genes linked to why ... others, according to a study released today that will ... Annual Meeting in Philadelphia, April 26 to May 3, ... it provides an objective way to understand pain and ... study author Tobore Onojjighofia, MD, MPH, with Proove Biosciences ...
(Date:4/18/2014)... The Gerontologist reports that among older Christians, ... in anxiety about death and increases in life satisfaction, ... particular, listening to gospel music is associated with a ... sense of control. , These associations are similar for ... both low- and high-socioeconomic status. , The article, titled ...
(Date:4/18/2014)... Benaroya Research Institute at Virginia Mason (BRI) recently received ... in metastatic breast cancer reduces both the growth of ... scientists have found in models of the disease that ... 80 percent and can keep the tumor from metastasizing ... grant comes from the National Cancer Institute of the ...
(Date:4/18/2014)... by Northwestern Medicine scientists could lead to potential new ... people with scleroderma. , Fibrosis, or scarring, is ... the skin and lungs can lead to serious organ ... for new therapeutic options centers on findings made by ... identified the role that a specific protein plays in ...
Breaking Medicine News(10 mins):Health News:Regulating legal marijuana could be guided by lessons from alcohol and tobacco, study says 2Health News:Low tolerance for pain? The reason may be in your genes 2Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2
... that only 2 in 5 seek any assistance, ... being,one of today,s most common disorders, it is regularly ... occasional feelings of anxiety -- muscle tension,headache, nausea, fatigue, ... speaking, first dates, or during times of stress such ...
... Diseases (NIAID), part of the National Institutes of ... Clinical Proteomics Centers for Infectious Diseases and Biodefense. ... Texas Medical Branch (UTMB), Galveston, and to the ... centers will analyze human blood and other tissue ...
... launch anticipated in early 2009 -, CORONA, ... WPI ), a leading specialty pharmaceutical,company, announced today ... approved RAPAFLO(TM) (silodosin), the company,s new alpha blocker ... BPH., BPH is the number one reason ...
... Celestial,Group, Inc. (Nasdaq: HAIN ), a leading ... today announced that Irwin Simon, President and,Chief Executive ... the,Company on Wednesday, October 15, 2008 at the ... http://www.newscom.com/cgi-bin/prnh/20050324/NYTH131 ), The investor presentation ...
... Robbins & Myers, Inc.,(NYSE: RBN ) ... a regular,cash dividend payment of $0.0375 per share. ... shareholders of record as of October 20, 2008., ... supplier of engineered equipment and,systems for critical applications ...
... Oct. 8 New physical activity guidelines,released today ... Services (HHS),will give Americans the information they need ... of the USA, the national resource office for ... Activity Guidelines for Americans set achievable,goals for everyone ...
Cached Medicine News:Health News:40 Million Americans Endure Anxiety Everyday 2Health News:NIAID awards contracts to search for protein markers of disease 2Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 2Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 3Health News:Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH) 4Health News:Hain Celestial to Present at Canaccord Adams Healthy Living Naturally Boston Conference on October 15, 2008 2Health News:YMCA of the USA Supports New National Physical Activity Guidelines 2
(Date:1/15/2014)... Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), a ... a non-invasive, wireless continuous glucose monitoring system, today announced ... Interim CEO of Echo Therapeutics, will present at "TEN", ... Mr. Doman will make a corporate presentation ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Argos Therapeutics announced today that interleukin ... dendritic cell (DC) immunotherapy and can be used as a ... company,s lead product, AGS-003, in metastatic renal cell carcinoma (mRCC). ... Immunotherapy demonstrate that the potency of mature CD40L RNA electroporated ...
... Rotational molder REMCON Plastics is already seeing process reduction ... organized under the leadership of new hire Benjamin F. ... REMCON,s Lean Manufacturing and Continuous Improvement Initiatives. He will ... active teams to sustain a strong, lean culture within ...
Cached Medicine Technology:Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial 2Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics' Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial 3Six Sigma Black Belt and Lean Sensei Ben Wittich Joins REMCON Plastics 2
Double-ended. Designated most popular model or size....
Designated most popular model or size. 3 mm tip....
Octagonal handle. 3 mm wide....
4 mm x 6 mm dissector end with shaft marked at 10 mm, 20 mm, 30 mm from tip. 6 mm wide curved elevator. Round knurled handle....
Medicine Products: